Elanco Animal Health (NYSE:ELAN) Downgraded by Zacks Research to “Hold”

Zacks Research downgraded shares of Elanco Animal Health (NYSE:ELAN) from a strong-buy rating to a hold rating in a research note published on Wednesday,Zacks.com reports.

Several other equities research analysts also recently issued reports on ELAN. Wall Street Zen upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. UBS Group increased their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Leerink Partnrs upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Piper Sandler increased their target price on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Finally, Stifel Nicolaus increased their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, July 2nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.33.

Elanco Animal Health Trading Up 2.3%

NYSE:ELAN opened at $17.8930 on Wednesday. The company has a market cap of $8.89 billion, a P/E ratio of 20.81, a P/E/G ratio of 3.25 and a beta of 1.66. The stock’s fifty day moving average price is $15.08 and its two-hundred day moving average price is $12.47. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $18.08. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Primecap Management Co. CA raised its position in shares of Elanco Animal Health by 3.1% in the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock worth $739,230,000 after buying an additional 1,543,279 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Elanco Animal Health by 14.3% during the first quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after purchasing an additional 2,563,740 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in Elanco Animal Health by 1.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company’s stock valued at $167,826,000 after purchasing an additional 292,655 shares in the last quarter. Shapiro Capital Management LLC raised its position in Elanco Animal Health by 7.5% during the fourth quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company’s stock valued at $149,640,000 after purchasing an additional 862,900 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in Elanco Animal Health during the first quarter valued at about $115,212,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.